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FOREWORD 
This work was carried out between 2008 and 2010 as a student research project in the Nesys 
laboratory as a part of Dr. Trygve B. Leergaard’s research project: “Structural Neural 
Network Changes in a Transgenic Rat Model for Huntington’s Disease”, funded by the 
Research Council of Norway. The transgenic animals were provided by Professor Stephan 
von Hörsten (University of Erlangen). The experimental work was conducted by Dr. Yvette 
C. van Dongen with assistance from research student Arnold Molvær. Eszter Papp assisted 
with image analysis. Histological processing and analyses were carried out by Molvær. The 
project was supervised by Drs. van Dongen and Leergaard. 
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ABSTRACT 
Huntington’s disease (HD) is hereditary disease, caused by an expanded trinucleotide repeat, 
which produces cognitive and motor defects, and premature death. Several mouse models 
have been produced to understand the cause and progression of the disease. However, these 
models have a short lifespan, and their brains are relatively small with respect to 
microsurgery. Recently, a homozygote rat model, transgenic for HD, which develops 
symptoms similar to the late onset form of the disease, has been produced. 
The major objective of this study was to evaluate the integrity of the frontal cortico-
striatal projection system in a transgenic rat model of HD, by assessing the loss of pyramidal 
cells in the frontal cortex in this model. We address the hypothesis that corticostriatal 
projections are reduced in old, symptomatic, transgenic HD rats as found in humans with the 
disease. We injected the tracer biotinylated dextran amine into the dorsomedial striatum in old 
transgenic rats (n = 4) and wildtype controls (n = 3), and counted the number of retrogradely 
labelled neurons in the medial prefrontal cortex. Labelled cells were primarily found in the 
prelimbic, dorsal anterior cingulated, and medial precentral areas, in correspondence with the 
known topographical arrangement of frontal corticostriatal afferents (Voorn 2004). 
 When the number of labelled prefrontal corticostriatal cells per mm3 of injected tracer 
in the transgenic HD rat models was compared with the control rats, we observed a found 
significantly reduced numbers of labelled neurons in the prefrontal cortex (p = 0.033). 
However, given the small sample size, we concluded that further investigations are 
recommended. 
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INTRODUCTION 
Huntington’s disease (HD) is an autosomal-dominant neurogenetic disorder causing motor 
and cognitive impairments and premature death. The gene responsible for HD encodes a 
protein called huntingtin (Gutekunst et al., 2002; Craufurd et al. 2002). A mutation within the 
coding sequence of the gene causes an abnormal expansion of CAG trinucleotide repeats (>28 
repeats) in the huntingtin protein. The wildtype huntingtin protein is thought to be associated 
with various intracellular processes that are essential for normal cell function (Li et al., 2004). 
The formation of neuronal inclusions and aggregates of mutant huntingtin are key features of 
the disease. Whether these fragments represent toxic or protective species remains to be 
clarified (Imarisio et al., 2008).  
 Another adverse effect, seen in the pathogenesis of HD, is selective 
neurodegeneration. The process of neuronal degeneration follows a heterogeneous and 
temporal pattern. The earliest and most prominent neuropathology is found in the basal 
ganglia (in particular the striatum), followed by many other subcortical and cortical brain 
regions, including the cerebral cortex (Gutekunst et al., 2002). In the cerebral cortex, 
topologically selective changes have been identified in symptomatic HD patients (Selemon et 
al., 2004). This includes regional cortical thinning of the prefrontal cortex (PFC) and is 
associated with pyramidal cell loss from cortical layers III, V and VI. 
 The clinical HD symptoms (i.e., motor, cognitive and psychiatric) have traditionally 
been explained by the dysfunction of the striatum  (Bonelli and Hofmann, 2007). However, 
there is now strong support for an alternative hypothesis on the growing role of the cerebral 
cortex in the progression of the disease (Lawrence et al., 1998; Cepeda et al., 2003; Rosas et 
al., 2008). This is further supported by the severe cognitive decline in the middle and late 
stages the disease. 
After the discovery of the gene responsible for HD (The Huntington’s Disease 
Collaborative Research Group, 1993), several transgenic animal models, including a non-
human primate model, have been generated (Hickey and Chesselet, 2003; Vonsattel, 2008; 
Heng et al., 2008; Bugos et al., 2009). Recently, the first transgenic HD rat model has been 
generated, bearing 51 CAG repeats, which mimics the progressive neurodegenerative changes 
as observed in adult onset human HD (von Hörsten et al., 2003). Genetically engineered 
animal models (those of the mice being most extensively studied, while the rat and non-
human primate models have only recently been generated) are now frequently used in order to 
improve our understanding of the pathophysiology of HD. The advantages of the transgenic 
HD rat model (compared to the mice models) are the longer life span (Ramaswamy, 2007) 
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and, in particular, the larger size of rats and especially the rat brain, which permits 
microsurgical techniques and neuroimaging procedures. 
  
AIM  
Cortical atrophy and neuropathology are key elements in the progression of HD, and these 
features are currently understudied. Given the progressive motor and cognitive decline as well 
as striatal pathology in these transgenic HD rats (von Hörsten et al., 2003; Bauer et al., 2005; 
Nguyen et al., 2006; Kántor et al., 2006; Cao et al., 2006; Winkler et al., 2006; Temel et al., 
2006; Petrasch-Parwez et al., 2007), it is relevant to evaluate the integrity of the underlying 
neural circuits. The PFC in particular is commonly implicated in cognitive functions and 
therefore it is likely that this cortical region is involved in the disease process. We 
hypothesize that cortical projection neurons in the medial PFC (mPFC) are reduced in old 
transgenic HD rats exhibiting symptoms of HD. To test this hypothesis, we injected the tracer 
(BDA) biotinylated dextran amine (Veenman et al., 1992; Reiner et al., 2006) into the 
dorsomedial striatum to retrogradely label the cortico-striatal neurons of the mPFC. The 
number of retrogradely labelled cortico-striatal neurons in the mPFC was quantified in 
transgenic HD rats and wildtype littermate controls.
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MATERIALS AND METHODS 
Animals. Experiments were conducted in five 470±5 days old male homozygous transgenic 
HD rats (TG group; +/+) and five wild-type littermate control animals (WT group; -/-) 
provided by our collaborator (Professor Stephan von Hörsten, Friedrich-Alexander 
University, Erlangen-Nürnberg, Germany). As earlier data (Nguyen et al., 2006) have shown 
that TG rats develop progressive symptoms of HD from an early age, and striatal atrophy 
from an age of 12 months, we here consider it likely that the here investigated 16-month-old 
TG rats have HD-like symptoms and neuropathology (see Fig. 1). As an additional control, 
experiments were also conducted on two normal 2-month-old male Sprague Dawley rats 
(SpD group; provided by the Norwegian Institute of Public Health, Oslo, Norway).  
All experimental procedures were approved by the local institutional welfare 
committee of the University of Oslo, in agreement with the European Community regulations 
on animal wellbeing, and the National Institutes of Health’s guidelines for the care and use of 
laboratory animals
 
 
Figure 1. A schematic representation of the rat’s lifespan in months, with phenotype changes 
as described in von Hörsten, 2003.  
 
 
Animal surgery, tracer injections and histochemistry. Surgical anaesthesia was induced 
using 5 % isoflurane in a gas chamber. Throughout the surgical procedure anaesthesia was 
maintained by administration of 2-3 % isoflurane through a muzzle. The rats were placed on a 
heating pad, and their heads immobilized in a stereotaxic frame using earbars and a toothbar. 
Vital parameters (heart rate, core body temperature) and level of anaesthesia (pedal reflex) 
were monitored during the whole procedure. Body temperature was maintained at 37°C using 
a rectal feedback system. Neutral eye ointment was applied to prevent retinal dehydration. 
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 An incision was made in the scalp, exposing the cranium. The orientation of the skull 
was adjusted so that the Lambda and Bregma landmarks were horizontally aligned. A small 
hole was drilled in the cranium at coordinates 1.20 mm posterior and 3.25 mm lateral relative 
to Bregma. BDA (10% 10kMw BDA in 0.1M sodium phosphate buffer [NaPi] pH 7.4) was 
iontophorically injected (10 µA, 7s/7s on/off, 30 min) into the dorsomedial striatum (4.5 mm 
below the surface, at a 25° angle) using a glass micropipette (inner diameter 20µm). 
Following the injection, the pipette was left in situ for 10 minutes, and then slowly retracted 
to reduce backflow of the tracer. The skin was sutured and 1 ml saline and Temgesic 
(0.3mg/ml; 0.1-0.3mg/kg) were injected subcutaneously after the surgery was completed. 
Nine experiments were successfully conducted, while one animal was euthanized before the 
procedure was completed.  
 After a 7 days postoperative period, the animals were re-anesthetized with Nembutal 
(100 mg/ml; 50mg/kg) intraperitoneally and transcardially perfused with 250-300 ml 9 % 
saline (at 37°C), followed by a 300 ml 4 % paraformaldehyde (PFA) solution, and finally 
250-300 ml of a 10% sucrose solution (at 4°C). All solutions were phosphate buffered and 
freshly prepared. Following perfusion, the brains were dissected out, and stored in a 30% 
sucrose solution refrigerated at 4°C until further processing. The lateral surface of the right 
hemisphere was marked with a shallow razor blade cut along its entire length. The angle of 
the sectioning of the coronal plane was defined by adjusting the dorsal surface of the brain 
into the horizontal plane, matching the flat skull position employed in the Paxinos and 
Watson atlas (2005). Coronal sections (50 µm thick) were cut using a freezing microtome. 
Each section was stored in separate wells filled with NaPi and 0.1% PFA for long-term 
storage at 4 °C. 
 Every second section from the forebrain was stained for BDA using Vectastain’s 
ABC-kit and DAB as a chromogen (enhanced by ammonium-nickel-sulphate), following 
steps 1-7 in Lanciego and Wouterlood (1994). Sections including the prefrontal cortex were 
subsequently counterstained with a standard Thionin staining, mounted, dehydrated and 
coverslipped using Eukitt mounting medium (Van Loenen Instruments, Zaandam, The 
Netherlands). 
 
Anatomical analysis. The distribution of BDA labelled cells in the left mPFC was mapped in 
every second section of the mPFC. In each case 24 sections were investigated. The numbers 
of BDA labelled neurons were recorded in digital section drawings made through a 10x 
objective using a motorized Zeiss Axioskop2 system running Neurolucida 7 
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(MicroBrightField Inc., Williston, VT, USA) software. In each drawing the boundaries of the 
mPFC subregions, the outer contour of the brain and the boundaries of the white matter 
(external capsule and corpus callosum) were outlined. 
The boundaries of the mPFC subregions (i.e., medial orbital (MO), infralimbic (IL), 
prelimbic (PL), dorsal anterior cingulate (ACd) and medial precentral (PrCm)) were 
delineated on the basis of cytoarchitectonically-defined criteria (Table 2; Palomera-Gallagher 
et al., 2004; Vogt et al., 2004; Heidbreder and Groenewegen, 2003; Uylings et al., 2003; Van 
de Werd and Uylings, 2008). In brief, PL, IL and ACd were located between the Fr2 and MO 
in mPFC. These boundaries were identified by the relatively thick layer I in this region. PL 
was distinguished from IL by the presence of a thick layer VI, a thin layer II, and a more 
distinct layer III. ACd was further distinguished from PL by the double lamination pattern in 
layer VI, and the homogenous layer III found in ACd. The frontal cortex was delineated on 
basis of the thin layer I (compared to the ACd, PL and IL), the densely packed pyramidal 
layers, and a very narrow layer IV, which is present in the previous subregions. Layer III, 
which is narrower in PrCm as compared to Fr1, was used to distinguish PrCm from Fr1, 
demarking the superior lateral border of mPFC. The MO was distinguished from the cingulate 
cortex by its thinner layer I (see also Table 2). 
In each subregion, the total number of recorded BDA labelled cells was counted. In 
order to normalize the number of BDA labelled cells to the size of the injection site, the 
injection size volumes were measured using an image analysis (Papp and Bjaalie, 2009). To 
achieve this, digital images of entire coronal sections were acquired with a slide scanner 
(Mirax Scan, Carl Zeiss MicroImaging GmbH, Jena, Germany). Selected parts of the images 
covering the BDA injection sites were exported from the Mirax Viewer software at reduced 
resolution (1:4, uncompressed TIFF format). The exported mages were binarized using 
ImageJ Autothreshold plug-in (National Institutes of Health, USA: http://rsbweb.nih.gov/ij. 
The binarization settings used for the injection sites were optimized to include the most 
densely stained core containing labelled neurons, while excluding the labelled fibres 
emanating from the injection site. Following binarization all images were filtered using a 
standard ImageJ medial filter of 1 pixel radius. The number of pixels, representing labelling, 
was counted, and labelled area was calculated on the basis of the known pixel size of the 
scanner and the known export resolution ratio. Furthermore, volumes were calculated for each 
series from area and distance separating the measured sections.
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RESULTS 
Tracer injection sites 
In the 12 experiments conducted, BDA was iontophoretically injected into the striatum. The 
injection sites were targeted to the dorsomedial striatum 1.2 mm posterior of bregma, at 500 
µm distance from the lateral ventricle. Two injection sites (one WT and one TG) involved the 
overlying white matter and were excluded from the study. The remaining ten injection sites 
were confined to the dorsomedial striatum (see Fig. 2). Four (out of 10) BDA injections also 
involved the subventricular zone (see Fig. 2). The injection sites were relatively similar in 
sizes, however, three (cases WT37, TG80 and TG32) somewhat smaller than the other 
injections (see Fig. 2; Table 3). In one WT control animal only two retrogradely labelled cells 
were observed in the prefrontal cortex. This was considered as a failed experiment, which was 
excluded from the study.  
Table 1- List of experimental animals included in the present study 
ANIMAL GROUPS CASE #  GENOTYPE AGE (days) WEIGHT (g) 
TS7 NA 80 420 SpD 
TS9 NA 94 414 
WT36 -/- 475 510 
WT37 -/- 470 571 
WT 
WT58 -/- 474 480 
TG31 +/+ 473 550 
TG32 +/+ 469 555 
TG52 +/+ 470 520 
TG 
TG80 +/+ 466 463   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Table 2 – Characteristic cytoarchitectonic medial prefrontal cortical areas 
AREA SYNONYMS CHARACTERISTIC FEATURES 
Layer III is narrower than in Fr1* Medial precentral 
(PrCm) 
Fr2, M2 
Thin but visible layer IV* 
Medial orbital (MO)   Layer II has a sharp border upon layers I and III*** 
ACd, like PL and IL, has a thick layer I, compared to other 
subareas* 
Layer III is rather homogeneous* 
No layer IV (agranular)* 
Layer V has large cells* 
Dorsal anterior 
cingulate (ACd) 
Cg1 
Layer VI is thick* 
Thick layer I, like ACd and IL* 
Layer III is poorly differentiated* and visible as a bright band 
between layers II and V*** 
No layer IV* 
Prelimbic (PL) PrL, Cg3 
Layer V is poorly differentiated* 
Thick layer I, like ACd and PL* 
Layer II is thick** 
Layer III is poorly differentiated** 
No layer IV* 
Layer V is thick** 
Infralimbic (IL) IL 
Layer VI is very thin ** 
* Palomera-Gallagher et al., 2004; **Vogt et al., 2004; ***Van de Werd and Uylings, 2008 
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Wildtype (-/-) rats 
WT36 
 
WT37 
 
WT58 
 
   
Homozygous (+/+) rats 
TG31 
 
TG32 
 
TG52 
 
TG80 
 
    
Normal Sprague Dawley rats 
TS7 
 
TS9 
 
  
 
Figure 2. Photomicrographs and corresponding binary image of the injection sites of the 
tracer biotinylated dextran amine (BDA) in the dorsomedial striatum with the largest 
diameter. 
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Table 3 - Injection site volumes 
CASE # TG31 TG32 TG52 TG80 WT36 WT37 WT58 TS7 TS9 
Injection site 
volume 
0,145 0,027 0,021 0,018 0,064 0,023 0,191 0,038 0,065 
 
 
 
Regional distribution of labelled cells 
Histochemistry for BDA revealed labelled cells featuring a typical granular labelling pattern 
(with or without labelled dendritic fragments; Fig. 3). The labelled cells were distributed 
throughout the mPFC (Table 4). In the mPFC subregions, the labelled cells were prominent in 
layer V, and to a lesser extent distributed in layers III and VI (Fig. 4, Table 5). No labelled 
cells were found in layers I, II and IV. In the medial precentral, dorsal anterior cingulated and 
PL areas, labelled cells were observed with a higher incidence than in the medial orbital and 
infralimbic areas (see Fig. 5 and Table 6). There was a qualitatively observed reduction in the 
number of labelled neurons in the TG rats compared to the WT. These observations had to be 
confirmed quantitatively, and corrected for their respective injection site sizes. 
 
Quantitative analysis  
We counted the number of labelled cells in the mPFC in the TG (n = 4) and wildtype (n = 4) 
rats, as well as in normal Sprague Dawley rats (n = 2). The labelled cells were found 
primarily in cortical layers III, V and VI. The WT and SpD rats had a majority of labelled 
cells in layer V, and, although, this is also true for the transgenic rats, the numbers were 
greatly reduced (Table 4). 
Since the amount of cells labelled are expected to be related to the size of the tracer 
injection site, we normalized the counted cell numbers to the injection site volume (see Fig. 7 
and Table 8). We then compared the number of cells labelled per injected volume of BDA 
between the three animal groups to test the hypotheses that the numbers of labelled prefrontal 
cortico-striatal cells reduced in old TG rats. We used an unpaired two-tailed t-test to measure 
statistical significance. 
 First, to assess control groups, we compared the number of labelled cells per mm3 
BDA in the wildtype and SpD groups (See Fig. 5 and Table 6). Since there was no significant 
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difference observed after comparing the numbers in a Student’s t-test (p=0.65), we lumped 
these two groups of animals in a common control group (n=5). 
 
 
B 
 
A 
 
C 
 
 
Figure 3. An example of the distribution of retrogradely labelled neurons in the medial 
prefrontal cortex (mPFC) of a wildtype rat. A) Neurolucida generated digital– recording of 
a coronal section showing the external brain surface (red), the boundary between cortical 
grey matter and the underlying white matter (yellow) as well as areal boundaries (white, 
grey, purple, and green lines), The blue triangles show the distribution of retrogradely 
labelled neurons in superficial and deep cortical layers. Each triangle represents a single 
labelled neuron. B is a low power photomicrograph of a thionin stained section, showing 
BDA labelled neurons in deep cortical layers. C is a magnification of the BDA labelled cell 
shown in B.  
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Table 4 – Areal and layer distribution of labelled cells in the medial prefrontal cortex 
AREA Layer TG31 TG32 TG52 TG80  WT36 WT37 WT58 TS7 TS9 Total 
MO I                     
  II                     
  III                     
  IV                     
  V 1     1 2   4      8 
  VI                     
IL I                     
  II                     
  III                     
  IV                     
  V             3     3 
  VI                     
PL I                     
  II                     
  III     4  4    7  15 
  IV                     
  V 6   35   35 7 34  69 13 199 
  VI     1   6 5 3  50 12 77 
ACd I                     
  II                     
  III       1   2 2    1 6 
  IV                     
  V   3 7   31 48 2  4 15 111 
  VI       1 1 5   3 12 22 
Fr2 I                     
  II                     
  III 5       1       1 7 
  IV                     
  V 1 6 4 2 33 14 1    39 100 
  VI   5     5 8   1 25 44 
Total   13 14 51 5 118 89 49 134 118 592  
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Figure 4 – Distribution of labelled cells in the medial prefrontal cortical subregions 
 
Table 5 
AREA TG31 TG32 TG52 TG80 Sum Meanx2  
MO 1     1 2 1  
IL           0  
PL 6   40   46 23  
ACd   3 7 2 12 6  
PrCm 6 11 4 2 23 11,5  
Total 13 14 51 5 83 41,5  
        
AREA WT36 WT37 WT58 TS7 TS9 Sum Meanx2 
MO 2   4      6 2,4 
IL     3     3 1,2 
PL 45 12 37  126 25 245 98 
ACd 32 55 4 7 28 126 50,4 
PrCm 39 22 1   1 65 128 51,2 
Total 118 89 49 134 118 508 203,2 
 
Since only every second section covering the medial prefrontal cortex was used, the mean is 
multiplied by two, in order to normalize the values. 
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Figure 5 
 
Table 6 
Layer WT36 WT37 WT58 Sum Meanx2 
I           
II           
III 5 2 2 9 6 
IV       0   
V 101 69 44 214 142,667 
VI 12 18 3 33 22 
Total 118 89 49 256 170,667 
 
Layer TS7 TS9 Sum Meanx2 
I         
II         
III 7 2 9 9 
IV     0 0 
V 73 67 140 140 
VI 54 49 103 103 
Total 134 118 252 252 
 
Since only every second section covering the medial prefrontal cortex was used, the mean is 
multiplied by two in order to normalize the values. 
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We then compared the total number of labelled cells per volume of injected tracer between 
the TG rats and the control rats (WT and normal SpD rats). The normalized, mean number of 
labelled cells was markedly lower in the TG group (41,5) compared to the control groups 
(203,2). A two-tailed Students t-test showed that this difference was statistically significant 
(p=0.033) at p < 0,05 (Fig. 6 and Table 7 & Fig. 7 and Table 8). 
Figure 6 – Distribution of labelled cells in layers I-VI of the medial prefrontal cortex 
 
Table 7 
Layer TG31 TG32 TG52 TG80 Sum Meanx2  
I              
II              
III 5   4 1 10 5  
IV              
V 8 9 46 3 66 33  
VI   5 1 1 7 3,5  
Total 13 14 51 5 83 41,5  
        Layer WT36 WT37 WT58 TS7 TS9 Sum Meanx2 
I               
II               
III 5 2 2 7 2 18 7,2 
IV               
V 101 69 44 73 67 354 141,6 
VI 12 18 3 54 49 136 54,4 
Total 118 89 49 134 118 508 203,2 
 Since only every second section covering the medial prefrontal cortex was used, the mean is 
multiplied by two in order to normalize the values. 
Figure 7 – Normalized data: number of labelled cortico-striatal neurons in the medial 
prefrontal cortex per volume tracer injected 
 
 
Table 8 
CASE # TG31 TG32 TG52 TG80 WT36 WT37 WT58 TS7 TS9 
Inj. site volume 
(mm3) 0.145 0.027 0.21 0.018 0.064 0.023 0.191 0.038 0.065 
Normalised cell 
number 26 28 102 10 236 178 98 268 236 
Cells per mm3 
tracer 179 1037 485 556 3688 7739 513 7053 3631 
 
The numbers of labelled cells normalized to the size of the injection site (TG rats (white) and 
the WT + SpD rats (grey)) 
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DISCUSSION 
To assess the integrity of the prefrontal cortico-striatal projections in TG rats, we retrogradely 
traced cortical neurons projecting to the dorsomedial striatum in old TG animals and WT 
littermates and SpD rats. Quantitative analysis of labelled cells in the medial prefrontal cortex 
shows a clear tendency towards reduced cortico-striatal projections in the TG animal group, 
which proved to be statistically significant level. 
The tracer BDA (10 kDa) is mainly used as an anterograde tracer, but it is also known 
to yield retrograde labelling (Reiner and Honig, 2006). It has been reported that the retrograde 
labelling properties of the tracer can be unpredictable (Vercelli et al., 2000), which could 
explain the variable numbers of labelled cells in the wildtype rats. The execution of the 
laboratorial procedures is also prone to both human and reagent errors. To reduce non-specific 
background staining, hydrogen peroxidase was used. Because there is no automatic way of 
quantification, human error in counting, overlooking cells, is also a factor to consider. By 
having two control recounts, with insignificant variations in the numbers, we tried to reduce 
the possibility of this error.  
 Despite the statistical significance, the observed results could be extremes within the 
normal distribution, and that the phenotypical observations merely coincidental. However, 
there are consistently low numbers of labelled cells observed in the homozygous TG rats 
when compared to the wildtype rats. To verify if the observed labelling is constant, we need a 
greater number of specimens to narrow the variation, so as to give a clear answer to the 
statistical significance of the reduced numbers. 
 Since the number of specimens used in the present study are few (n = 4), the findings 
can be interpreted as an indication of what we can expect in future studies. Though there is 
some variation present, the tendency is clear, suggesting that this study needs more specimens 
and the use of a pure retrograde tracer to give conclusive evidence. 
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